bioihbjkbjnl/mcl2 huggingface dataset:
Loss of Resistance, w/wo Stimulation, For Epidural Placement
Condition: Anesthesia
Intervention: Thoracic epidural block; Electrical Nerve stimulation; Solution For Thoracic epidural block
Intervention description: Thoracic epidural block with epidural placed with a loss of resistance technique alone.; In the electrical stimulation group, following the location of the epidural space with a loss of resistance technique (using air), nerve stimulation will be utilized to elicit a myotomal contraction of the abdominal or thoracic wall.stimulating peripheral nerve catheters(19 Ga. x 90 cm StimuCath® Continuous Nerve Block Catheter with SnapLock™ Adapter (Arrow by Teleflex Medical, Morrisville, NC), and stimulation will be achieved using a B Braun Stimuplex HNS12 Nerve Stimulator product id 4892098.; Dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine
Intervention MeSH terms: Lidocaine; Epinephrine
Phase: Phase 4
Study type: Interventional
Primary purpose: Supportive Care
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Masking description: As the patient will be sedated during epidural catheter placement, they will be blinded to their treatment arm. The investigator that determines if the epidural was successful placed will also be blinded to the patient's treatment arm.
Enrollment: 100.0
Sex: All
Minimum age: 18 Years
Maximum age: 90 Years
Healthy volunteers: No
Keywords: epidural catheter placement

Summary:

      The purpose of this randomized, observer-blinded, investigative trial is to determine if the
      use of electrical stimulation, compared to the traditional loss of resistance technique
      alone, improves the success rate of epidural catheter placement at an academic teaching
      institution.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Adults undergoing intra-thoracic or intra-abdominal procedures that normally would
             receive thoracic epidurals for post-operative analgesia will be eligible.

        Exclusion Criteria:

          -  Subjects with contraindications to regional anesthesia:

          -  history of allergy to amide local anesthetics

          -  presence of a progressive neurological deficit

          -  patients that are on anticoagulant medications that prohibit placement of an epidural

          -  Systemic infection

          -  Infection at the site of placement
Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients
Condition: Hepatitis B Vaccine
MeSH terms: Hepatitis A; Hepatitis B; Hepatitis
Intervention: 60 µg dose hepatitis B vaccine; 20 µg dose hepatitis B vaccine
Intervention description: three-dose, 60 µg per dose; three-dose, 20 µg per dose
Intervention MeSH terms: Vaccines
Phase: Phase 4
Study type: Interventional
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 352.0
Sex: All
Minimum age: 18 Years
Maximum age: 70 Years
Healthy volunteers: No
Keywords: Hepatitis B, Vaccine; Randomized Controlled Trial; Hemodialysis; Immunogenicity

Summary:

      Intramuscular injection of 40 μg hepatitis B vaccine in a standard three-dose schedule or a
      four-dose schedule is recommended for hemodialysis patients. However, seroconversion rates
      are inadequate and persistence of immunity remains a challenge.

      This is a randomized, controlled trial. The study will evaluate the immunogenicity, immune
      persistence, and safety of 20 µg and 60 µg recombinant hepatitis B vaccine with three
      injections at months 0, 1, and 6 in hemodialysis patients.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Having end-stage renal disease (ESRD) on maintenance hemodialysis

          -  Aged between 18 and 70 years at enrollment

          -  Serologically negative for hepatitis B surface antigen (HBsAg) and hepatitis B surface
             antibody (anti-HBs) at enrollment

          -  Willing to adhere to the study protocol

        Exclusion Criteria:

          -  Being pregnant

          -  Acute cytolysis in the last three months before enrollment

          -  Any vaccination during the month preceding enrollment

          -  Intolerance or allergy to any component of the vaccine

          -  Ongoing opportunistic infection

          -  Hepatitis C virus infection

          -  Hematological disorder

          -  Cancer

          -  Unexplained fever the week before enrollment

          -  Immunosuppressive or immunomodulating treatment in the last six months

          -  Renal transplantation or upcoming renal transplantation

          -  Liver disease

          -  Other immunocompromised condition not related to ESRD

          -  An expected survival of < 6 months
Evaluating Fluid Strategies in Thoracic Surgery Patients Utilizing a Goal Directed Approach
Condition: Hypotension; Kidney Injury
MeSH terms: Hypotension
Intervention: Plasmalyte 3ml/kg/hr group; Plasmalyte 6ml/kg/hr group
Intervention description: This group will have intravenous plasmalyte fluid limited to a rate of 3 ml/kg/hr. and a nexfin monitor placed on them; This group will have intravenous plasmalyte fluid limited to a rate of 6 ml/kg/hr. and a Nexfix Monitor placed on them
Intervention MeSH terms: Plasma-lyte 148
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Enrollment: 40.0
Sex: All
Minimum age: 18 Years
Maximum age: 89 Years
Healthy volunteers: No
Keywords: Hypotension; Kidney injury

Summary:

      The purpose of this study is to conduct a prospective, randomized, controlled trial comparing
      a restrictive vs. conservative fluid strategy in thoracic surgery patients. Excessive
      perioperative fluid has been retrospectively implicated in the development postoperative
      acute lung injury (PALI) and pulmonary edema following lung resection. However, fluid
      restriction in these patients is not without risk and may compromise end organ perfusion
      (i.e. acute kidney injury). The hypothesis is that a conservative fluid approach in thoracic
      surgery patients will result in better end organ perfusion with fewer occasions of acute
      kidney injury (AKI) without causing an increase in postoperative acute lung injury or
      pulmonary edema.
    

Eligibility criteria:

        Inclusion Criteria:

          -  between 18-89 years of age

          -  undergoing pulmonary lobectomy with open or video assisted thoracotomy

        Exclusion Criteria:

          -  patient refusal

          -  pregnancy

          -  cardiac arrhythmia

          -  pacemaker dependency

          -  severe aortic insufficiency

          -  idiopathic hypertrophic subaortic stenosis

          -  prisoners

          -  decisionally challenged

          -  patients that refuse to receive intravenous fluid products made from human plasma
             (Albumin 5%)

          -  patients with skin infection or breakdown on their fingers

          -  severe peripheral vascular disease

          -  evidence of compromised finger perfusion will be excluded
Dexamethasone for the Prevention of Post-operative Nausea and Vomiting in Patients Undergoing Cesarean Sections
Condition: Postoperative Nausea and Vomiting
MeSH terms: Nausea; Vomiting; Postoperative Nausea and Vomiting
Intervention: Dexamethasone; Placebo
Intervention description: 8mg IV dexamethesone given; Subjects randomized to placebo receive 50cc normal saline
Intervention MeSH terms: Dexamethasone
Phase: Phase 4
Study type: Interventional
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 122.0
Sex: Female
Minimum age: 18 Years
Maximum age: 46 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: cesarean section; nausea; vomiting; dexamethasone; postoperative nausea and vomiting; antiemetics

Summary:

      Patients who present for scheduled (non-emergent) cesarean section will be given either
      intravenous dexamethasone or placebo prior to receiving a duramorph containing spinal
      anesthetic. The investigators will then compare the incidence of nausea and vomiting and the
      use of rescue anti-nausea medications in both groups. Our hypothesis is that patients
      receiving dexamethasone prior to duramorph containing spinal anesthesia for cesarean section
      will have a significantly lower incidence and severity of PONV at 0, 1, 3, 6, and 24 hours
      following surgery.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Women aged 18-46 presenting for scheduled primary or repeat cesarean sections and have
             consented to study

        Exclusion Criteria:

          -  allergy to dexamethasone or morphine

          -  history of gastrointestinal disease

          -  history of severe nausea during pregnancy (hyperemesis gravidarum)

          -  use of anti-emetic in the past 24 hours

          -  history of gestational diabetes or diabetes mellitus

          -  history of hypertension prior to or during pregnancy

          -  presence of non-viable fetus
Platelet-rich Plasma vs. Hyaluronic Acid for Glenohumeral Osteoarthritis
Condition: Osteoarthritis; Shoulder Pain
MeSH terms: Osteoarthritis; Shoulder Pain
Intervention: PRP; Hyaluronic Acid; Ultrasound
Intervention MeSH terms: Hyaluronic Acid
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Enrollment: 70.0
Sex: All
Minimum age: 18 Years
Maximum age: 100 Years
Healthy volunteers: No

Summary:

      This study seeks to expand the current literature in demonstrating potentially efficacious,
      conservative treatments in the management of glenohumeral osteoarthritis (OA) and will
      compare ultrasound-guided injections of hyaluronic acid vs. platelet-rich plasma. We aim to
      obtain information measuring potential benefits of these interventions and to observe for any
      adverse events.
    

Eligibility criteria:

        Inclusion Criteria:

          -  English speaking/literate

          -  Age 18-100 years

          -  Visual analog score pain >= 5

          -  Greater than or equal to 3 months of pain after onset of symptoms that has failed
             conservative treatments

          -  Confirmation of glenohumeral OA via routine imaging (MRI and x-ray; must be recent and
             within the past year)

          -  Transient relief of symptoms after diagnostic intra-articular injection into the
             glenohumeral joint

        Exclusion Criteria:

          -  Non-English speaking/illiterate

          -  Painful active, concurrent cervical spine conditions

          -  Current non-steroidal anti-inflammatory drug (NSAID) use

          -  History of taking coumadin or similar anticoagulant, have a known coagulopathy,
             bleeding dyscrasia, or platelet count < 150,000/cubic mm

          -  Allergic reaction to poultry or previous viscosupplementation

          -  Involved in workers' compensation or active litigation involving affected shoulder

          -  Inability to refrain from NSAID use for 5 days prior to and 6 weeks after injection

          -  History of corticosteroid injection to affected shoulder within the last 3 months

          -  History of viscosupplementation or platelet-rich plasma to affected shoulder within
             the last 6 months

          -  Presence of acute fracture

          -  History of shoulder tumor

          -  Known uncontrolled systemic illness (uncontrolled diabetes, human immunodeficiency
             virus, vasculitis, autoimmune/inflammatory disease)

          -  Psychiatric and somatoform disorders
Recovery Profile Comparison Between Remifentanil-propofol or Desflurane Anesthesia Monitored With Bispectral Index.
Condition: Delayed Emergence From Anesthesia
MeSH terms: Delayed Emergence from Anesthesia
Intervention: Desflurane; Propofol
Intervention description: Balanced anesthesia with remifentanil and desflurane guided by bispectral monitoring; Total intravenous anesthesia based on propofol
Intervention MeSH terms: Propofol; Desflurane
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Enrollment: 40.0
Sex: Female
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Airway extubation; Anesthesia Recovery Period; Desflurane; Propofol; Intravenous anesthesia; Balanced Anesthesia

Summary:

      Bispectral monitoring anesthesia with remifentanil-desflurane has a better post-operative
      recovery than remifentanil-propofol.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Female patients over 18 years old classified by the American Society of
             Anesthesiologists as physical status I or II, undergoing elective breast surgery with
             general anesthesia.

        Exclusion Criteria:

          -  History of: illegal drug and alcohol abuse

          -  Pregnancy on course or suspicion of

          -  Neuromuscular disorders

          -  Cerebral vascular disease

          -  Dysphagia

          -  Dysphonia

          -  Gastroesophageal reflux disease

          -  Previous larynx and/or upper gastrointestinal tract surgery

          -  Allergy to any drug to be used and malignant hyperthermia.

          -  Patients who develop hemodynamic instability in the surgery and need blood transfusion
             were excluded from the study.

          -  Patients unable to swallow 20 ml of water in an upright position were also excluded.
UW-CTRI Triple Medication Smoking Cessation Study
Condition: Smoking
Intervention: Varenicline; Nicotine Transdermal Patch; Nicotine Mini
Intervention description: Standard FDA approved 12 weeks of treatment with Varenicline; Standard FDA approved 12 weeks of treatment with Nicotine Transdermal Patch; Standard FDA approved 12 weeks of treatment with Nicotine Mini-Lozenge
Intervention MeSH terms: Nicotine; Varenicline
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 36.0
Sex: All
Minimum age: 18 Years
Maximum age: 99 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: medication tolerability

Summary:

      This study will focus on enhancing future smoking cessation treatment effectiveness by
      piloting a potentially more powerful combination of three FDA-approved pharmacotherapies:
      varenicline plus combination of two types of nicotine replacement therapy (NRT) treatment
      (nicotine lozenge and nicotine patch). Data from this pilot study will help inform the design
      of future studies that would use this combination treatment as a cessation tool within the
      chronic care arsenal of treatments.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Age >17 years;

          -  >=5 cigarettes/day for the previous 6 months;

          -  alveolar CO >= 6 ppm; able to read, write and speak English;

          -  planning to remain in the intervention catchment area for at least 4 months; not
             currently taking bupropion or varenicline;

          -  if the participant is currently using NRT, s/he agrees to use only study medication
             for the duration of the study;

          -  free of medical contraindications to NRT and varenicline; and,

          -  if participant is a woman of childbearing potential, using an approved method of birth
             control during treatment.

        Exclusion Criteria:

          -  Current diagnosis of/treatment for psychosis or bipolar disorder;

          -  suicidal ideation within the past 12 months; any history of suicide attempts; *
             significant hepatic or renal impairment; history of significant allergic reactions to
             varenicline or any type of NRT in the past;

          -  use of any investigational drugs in the previous 30 days. -
Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose
Condition: Encephalitis, Japanese
MeSH terms: Encephalitis, Japanese; Encephalitis
Intervention: Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine
Intervention description: 0.5 mL subcutaneous injection
Phase: Phase 4
Study type: Interventional
Primary purpose: Prevention
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 561.0
Sex: All
Minimum age: 43 Months
Maximum age: 51 Months
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Japanese Encephalitis Vaccines; Flavivirus Infections

Summary:

      This study aims to understand the persistence of the Japanese encephalitis (JE) antibody
      response in previously vaccinated children. The proposed study will enrol Bangladeshi
      children who had previously participated in a lot to lot consistency study (JEV05;
      NCT01567865) of JE live attenuated SA 14-14-2 vaccine (CD-JEV).
    

Eligibility criteria:

        Inclusion Criteria:

          -  Participant in JEV05 study (NCT01567865) and received one dose of CD-JEV.

          -  Resides in the Matlab or Mirpur study area.

          -  At least one parent or guardian willing to provide written informed consent.

        Exclusion Criteria:

          -  Received a second dose of Japanese encephalitis vaccine within the past three years.

          -  Received immunoglobulins and/or any blood products within 90 days prior to enrollment.

          -  Been diagnosed with a primary or acquired immunodeficiency, including human
             immunodeficiency virus (HIV) infection within the past three years.
IV Acetaminophen for Postoperative Pain Analgesia After Laparoscopic Hysterectomy
Condition: Pain
Intervention: IV acetaminophen; placebo
Intervention description: The patients in the treatment arm will receive 1000mg of IV acetaminophen.; The patients in the placebo arm will receive normal saline.
Intervention MeSH terms: Acetaminophen
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Enrollment: 183.0
Sex: Female
Minimum age: 18 Years
Maximum age: 75 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Laparoscopic Hysterectomy; IV acetaminophen; Postoperative pain control; Surgery

Summary:

      The objective of this study is to quantify the change in post-operative pain scores and
      narcotic requirements in women receiving pre and post-operative IV acetaminophen compared to
      placebo in women undergoing laparoscopic hysterectomy.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Women aged 18-75

          -  Ability to read and write in English (our post-operative pain log is only available in
             English)

          -  Planning a laparoscopic hysterectomy (includes total laparoscopic hysterectomy,
             laparoscopic supracervical hysterectomy, laparoscopically assisted vaginal
             hysterectomy, with or without salpingooophorectomy)

        Exclusion Criteria:

          -  Answering yes to any of the following questions: "Do you have a history of liver
             disease, kidney disease, hepatitis C, history of liver failure, greater than 3 drinks
             per day or being have you ever been told by your doctor that they should not take
             acetaminophen"

          -  History of cardiac arrhythmia

          -  History of jaundice

          -  Acute abdominal inflammatory or infectious process at time of surgery

          -  Known malignancy at time of surgery

          -  Known pregnancy at time of surgery

          -  Plan to perform additional significant surgical procedure at the time of hysterectomy
             such as extensive excision of endometriosis on bowel or bladder or pelvic
             reconstructive procedure

          -  >6cm abdominal incision in order to remove the uterus at time of study-related
             hysterectomy

          -  Regular use of narcotic pain medication (defined as use on most days of the week at
             any point in the past 3 months)

          -  Allergy to acetaminophen

          -  Women who weigh less than 50 kilograms on the day of surgery.
Mixed Methods Investigation of Chronic Facial Paralysis in Individuals With Synkinesis
Condition: Synkinesis
MeSH terms: Bell Palsy; Facial Paralysis; Paralysis; Synkinesis
Intervention: Neuromuscular Retraining Therapy (4 months); Chemodenervation (4 months); Neuromuscular Retraining + Chemodenervation
Intervention description: Neuromuscular retraining is an intervention where facial therapists utilize voluntary input to access improved movement patterns in patients with synkinesis.; A neurotoxin that temporarily reduces muscle activity and minimizes the effects of uncoordinated muscle.; Participants will receive both interventions for the last 4 months of their time on study.
Intervention MeSH terms: Botulinum Toxins, Type A
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Enrollment: 15.0
Sex: All
Minimum age: 18 Years
Maximum age: 89 Years
Healthy volunteers: No

Summary:

      This proposal will prospectively assess the social, physical, and emotional recognition
      function in participants with synkinesis. It will measure the effectiveness of neuromuscular
      retraining therapy to improve muscle coordination compared to chemodenervation, the more
      established treatment modality, in a single-blinded, randomized control trial using
      clinician- and patient-reported outcomes measures. The hypothesis tested is that participants
      undergoing neuromuscular retraining therapy will achieve greater improvement on clinical
      outcome measures as compared to participants receiving chemodenervation.

      In this clinical trial, 36 participants undergoing treatment for synkinesis will be enrolled
      into one of two treatment arms: chemodenervation or neuromuscular retraining therapy.
      Participants can expect to be on study for approximately 8 months.

      Participants who enroll in this mixed methods investigation will be recruited from patients
      of the University of Wisconsin Facial Nerve Clinic and also be enrolled in a another study
      for assessment [Perception of Emotion Expression in Clinical Populations with Facial
      Paralysis, IRB approval 2015-0366].
    

Eligibility criteria:

        Inclusion Criteria:

          -  Has ipsilateral synkinesis of facial muscles

          -  It has been at least four months since their onset of peripheral facial paralysis from
             any cause

          -  Ability to read and write in English

        Exclusion Criteria:

          -  previous treatment with reanimation surgery (except for upper eyelid weight placement)

          -  intolerance or contraindication to botulinum toxin injection

          -  previous treatment for synkinesis with chemodenervation or neuromuscular retraining
             therapy

          -  pregnant and/or breastfeeding women

          -  participants with impaired decision-making capacity, including those with severe
             psychiatric illnesses